Piramal Pharma Ltd Q1 FY27 Standalone Net Profit Rs. 113.48 Crores
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 08:45 PM IST · BSE ID: 267313ad-2c90-4d5f-86eb-1b48134331a4
View Original BSE Filing (PDF)
💡
In Simple Terms
Piramal Pharma's board approved its latest quarterly financial results, showing its earnings and expenses.
🤖 AI Summary
- Board approved Unaudited Standalone and Consolidated Financial Results for quarter ended June 30, 2026.
- Standalone revenue from operations was Rs. 1,124.95 Crores for the quarter ended June 30, 2026.
- Standalone Net Profit after tax reached Rs. 113.48 Crores for the quarter ended June 30, 2026.
- Consolidated revenue from operations stood at Rs. 2,269.92 Crores for the quarter ended June 30, 2026.
- Consolidated Net Loss after tax was Rs. (69.39) Crores for the quarter ended June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
1,124.95 Rs. in Crores
16.0%
Standalone Net Profit after tax (Q1 FY27)
113.48 Rs. in Crores
0.3%
Consolidated Revenue from operations (Q1 FY27)
2,269.92 Rs. in Crores
17.49%
Consolidated Net Profit/ (Loss) after tax (Q1 FY27)
(69.39) Rs. in Crores
🏢 How This Affects the Company
The company reported an increase in standalone revenue from operations to Rs. 1,124.95 Crores compared to Rs. 969.88 Crores in the prior year comparable quarter.
Standalone Net Profit after tax for the quarter was Rs. 113.48 Crores. Consolidated Net Loss after tax was Rs. (69.39) Crores, compared to a net profit of Rs. (81.70) Crores in the prior year comparable quarter.
The consolidated financial results indicate a net loss after tax of Rs. (69.39) Crores for the quarter, following a consolidated net loss of Rs. (325.94) Crores for the year ended March 31, 2026.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any immediate action based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as these are the latest quarterly financial results, providing an overview of the company's financial performance.
🔍
Management Signal
The management's signal is to maintain transparency by regularly disclosing financial performance in accordance with SEBI regulations.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — monitor consolidated net loss trend.
Management commentary on reasons for consolidated loss vs. standalone profit.
Update on plans to improve consolidated profitability and expense management.
MEDIUM RISK
Persistent consolidated losses, despite standalone profit, present a financial risk for the company.
💡 Investor Takeaway
Piramal Pharma Ltd reported standalone revenue from operations of Rs. 1,124.95 Crores in Q1 FY27, a 16.0% increase YoY. Standalone net profit after tax was Rs. 113.48 Crores, while consolidated net loss after tax was Rs. (69.39) Crores.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Revenue from operations increased to Rs. 1,124.95 Crores for Q1 FY27 from Rs. 969.88 Crores in Q1 FY26.
- Standalone Net Profit after tax of Rs. 113.48 Crores for Q1 FY27 is comparable to Rs. 113.14 Crores in Q1 FY26.
⚠️ Concerns
- Consolidated Net Loss after tax of Rs. (69.39) Crores for Q1 FY27, compared to a loss of Rs. (81.70) Crores in Q1 FY26.
- Standalone Profit before tax decreased to Rs. 149.48 Crores in Q1 FY27 from Rs. 331.85 Crores in Q4 FY26.
📅 Company Track Record
Piramal Pharma Limited was incorporated on March 1, 2020 (CIN: L24297MH2020PLC338592). It has a relatively recent operational history as an independent listed entity. The company's prior financial year ended March 31, 2026, reported a standalone Net Profit after tax of Rs. 700.01 Crores and a consolidated Net Loss after tax of Rs. (325.94) Crores.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Piramal Pharma's standalone revenue from operations for the quarter ended June 30, 2026?
Piramal Pharma's standalone revenue from operations for the quarter ended June 30, 2026, was Rs. 1,124.95 Crores.
What was Piramal Pharma's standalone Net Profit after tax for the quarter ended June 30, 2026?
Piramal Pharma reported a standalone Net Profit after tax of Rs. 113.48 Crores for the quarter ended June 30, 2026.
What was Piramal Pharma's consolidated revenue from operations for the quarter ended June 30, 2026?
Piramal Pharma's consolidated revenue from operations for the quarter ended June 30, 2026, was Rs. 2,269.92 Crores.
What was Piramal Pharma's consolidated Net Profit or Loss after tax for the quarter ended June 30, 2026?
Piramal Pharma reported a consolidated Net Loss after tax of Rs. (69.39) Crores for the quarter ended June 30, 2026.
What was Piramal Pharma's Basic EPS (Standalone) for the quarter ended June 30, 2026?
Piramal Pharma's Basic EPS (Standalone) for the quarter ended June 30, 2026, was Rs. 0.85 per equity share.
Questions based on this BSE filing only. For information purposes.